ETC
CPRX

Exchange Traded Concepts’s Catalyst Pharmaceutical CPRX Stock Holding History

Exchange Traded Concepts’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Sell
62,553
-7,234
-10% -$172K 0.01% 668
2025
Q4 		$1.63M Buy
69,787
+6,816
+11% +$152K 0.01% 639
2025
Q3 		$1.24M Buy
62,971
+61,250
+3,559% +$1.26M 0.01% 702
2025
Q2 		$37.3K Buy
1,721
+132
+8% +$3.12K ﹤0.01% 1342
2025
Q1 		$38.5K Sell
1,589
-550
-26% -$12.4K ﹤0.01% 1235
2024
Q4 		$44.6K Buy
2,139
+132
+7% +$2.84K ﹤0.01% 1233
2024
Q3 		$39.9K Sell
2,007
-21,072
-91% -$391K ﹤0.01% 1218
2024
Q2 		$357K Buy
23,079
+21,963
+1,968% +$342K 0.01% 747
2024
Q1 		$17.8K Sell
1,116
-160
-13% -$2.41K ﹤0.01% 1078
2023
Q4 		$21.4K Sell
1,276
-29,960
-96% -$410K ﹤0.01% 1042
2023
Q3 		$365K Buy
+31,236
New +$418K 0.01% 716

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Exchange Traded Concepts's CPRX Position: Q1 2026 in Review

Exchange Traded Concepts reduced its Catalyst Pharmaceutical (CPRX) stake by 10% in Q1 2026, selling an estimated $172K and leaving 62,553 shares worth $1.55M. The position accounts for 0.01% of the portfolio, ranked #668.

Exchange Traded Concepts first reported a position in CPRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.63M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Exchange Traded Concepts held 62,553 shares of Catalyst Pharmaceutical worth $1.55M as of Q1 2026.
  • Exchange Traded Concepts sold 7,234 Catalyst Pharmaceutical shares in Q1 2026, an estimated $172K.
  • Catalyst Pharmaceutical made up 0.01% of Exchange Traded Concepts's portfolio in Q1 2026, its #668 holding.
  • Exchange Traded Concepts first reported a position in Catalyst Pharmaceutical in Q3 2023 and has held it in 11 quarters since.
  • Exchange Traded Concepts's Catalyst Pharmaceutical position peaked at $1.63M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Exchange Traded Concepts's 13F filing for Q1 2026, filed 15 Apr 2026.